Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229143 | 0.84 | NPC1 (0.37) | NPC1 | |
| SCHEMBL5229676 | 0.83 | NPC1 (0.34) | NPC1 | |
| SCHEMBL5230836 | 0.83 | CHRM2 (0.34) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL5227049 | 0.82 | CYP1A2 (0.34) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL4696533 | 0.80 | NPC1 (0.34) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL5225145 | 0.78 | MAPK1 (0.37) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL4696041 | 0.75 | LMNA (0.37) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL5230891 | 0.73 | LMNA (0.37) | NPC1LMNACHRM2CHRM4CYP3A4 | |
| SCHEMBL4693175 | 0.72 | NPC1 (0.33) | NPC1 | |
| SCHEMBL4697528 | 0.71 | BRD4 (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312203-B2 | 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o. (HR) | 2007-12-25 | — | — | US | claimed |
| EP-1506202-B1 | 1-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2007-08-08 | — | — | EP | claimed |
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | claimed |
| EP-1684746-A1 | USE OF 1-AZA-DIBENZO[e,h]|AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-08-02 | — | — | EP | claimed |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| WO-2005049011-A1 | USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-02 | — | — | WO | claimed |
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | NPC1 812/4885LMNA 2555/4885CHRM2 107/4885 |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | NPC1 3522/4885LMNA 4419/4885CHRM2 3392/4885 |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | NPC1 3480/4885LMNA 4390/4885CHRM2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.